Protest Letter to Novo Nordisk Fonden
Are you frustrated by the belief that lingering symptoms of thyroid disease is due to mental illness? Do you want your voice heard by the company who is honoring Anthony Weetman who promoted this belief? Simply “COPY and PASTE” this letter and e-mail it to Novo Nordisk Fonden at email@example.com before they award Weetman the H.C. Jacobaeus Lecture Prize 2012 on November 29th. Thank you!
Birgitte Nauntofte, PhD
Novo Nordisk Fonden
Tuborg Havnevej 19
November 25, 2012
Good day, Ms. Nauntofte:
Thank you and Novo Nordisk Fonden for your contributions to the medical community especially in the care of diabetes. Recently, we have become aware of the intended recipient of “The H.C. Jacobaeus Lecture Prize 2012″ and this decision concerns ThyroidChange, an international collaboration of more than 7,000 individuals united in the belief that the current guidelines in the field of Endocrinology are not sufficient and diminish the quality of life for many patients. This letter demonstrates that our community does NOT support the decision to honor Anthony Weetman due to his misperception of thyroid disease, Novo Nordisk’s perceived endorsement of his misperception, and the impact this will have on our patient population.
Weetman’s (2006) article, “Whose Thyroid Hormone Is It anyway,” in the Journal of Clinical Endocrinology caused an uproar in the thyroid patient community. His paper posits that patients who are symptomatic with optimal TSH ranges have functional somatoform disorders. This blanket statement fails to identify the inadequacy of current thyroid treatment and instead, dismisses the patient and his or her complaints as mental disease.
ThyroidChange believes that current recommendations regarding the treatment of thyroid disease across the globe are inadequate. Frequently, patients remain symptomatic when their TSH value is in range. Patient experience and current research demonstrates that testing such as Free T4, Free T3 and Reverse T3 reveals what TSH does not: patients frequently remain hypothyroid at the cellular level despite treatment with synthetic levothyroxine. Currently, our community is working hard to unite the thyroid community and mainstream the voice of the suffering patient expressing this fact.
Novo Nordisk is endorsing Weetman’s misperception of thyroid disease and perpetuating the incorrect assumption that lingering symptoms of thyroid disease mismanagement are due to mental disease. This endorsement by such a reputable company worries thyroid patients. Research is continuing to demonstrate the insufficiency of current thyroid treatment and the need for treatment options tailored to the individual patient. This trend is beginning to liberate the individual thyroid patient and increase patient access to effective treatment of thyroid disease, however, these advances will be affected by honoring Weetman. Thyroid patients worldwide are impacted by Novo Nordisk’s decision which will add false value to Weetman’s misperceptions of thyroid disease. Your organization will become complicit in the continued suffering of our community.
In an effort to protect the patients who will suffer as a result Weetman’s honor, ThyroidChange strongly requests that you reconsider the recipient of The H.C. Jacobaeus Lecture Prize 2012 before presenting it on November 29th.Thank you for your time and consideration. Please be advised that our community of over 7,000 individuals united for improved thyroid care (including numerous physicians who have employed the above detailed treatment perspectives) are available to share our experiences at your discretion.
Together, we can create effective change.